top of page
Browse by category
Search


Panther Healthcare’s endostapler is safe and effective in RYGB patients
Brazilian researchers have reported that Panther Healthcare’s endostapler is safe and effective in patients undergoing Roux en Y gastric...


Bariatric surgery is associated with reduced all-cause and CV mortality
Researchers from The Netherlands have reported that bariatric surgery is associated with reduced all-cause and cardiovascular (CV)...


World Obesity Federation: 1 billion people living with obesity by 2030
The World Obesity Federation has published its fourth World Obesity Atlas, which this year provides predictions for the prevalence of...


Review paper examines evidence of bariatric surgery to reduce obesity-associated breast cancer
A review paper has sought to clarify the relationship between obesity and breast cancer, and explore the potential role of bariatric...


Gore Symposium (EMEA & Australia): Meet the Experts - Obesity and the Associated Diseases
Last year, Gore sponsored a live webinar symposium for EMEA and Australian surgeons which featured a panel of EMEA experts who discussed...


Benefits of staple line reinforcement, but more evidence needed
Suture oversewing (SR) during laparoscopic sleeve gastrectomy (LSG) seems to be associated with a reduced risk of postoperative bleeding,...


Gastric bypass better for type 2 diabetics
Roux-en-Y gastric bypass (RYGB) leads to greater weight loss and a greater rate of remission of diabetes than sleeve gastrectomy or...


Stimulating signalling could improve metabolic health and treat obesity
Researchers from the University of Colorado School of Medicine have reported that finds an epigenetic modifier known as histone...


RYGB more efficient than SG and more evidence is needed for OAGB
Roux-en-Y gastric bypass (RYGB) is more efficient (excess weight loss, EWL percentage) than sleeve gastrectomy (SG) after five years,...


Three trials to assess ARD-101 including for refractory weight gain post-bariatric surgery
Enrolment has begun in three Phase 2 studies of ARD-101, a first-in-class small molecule bitter taste receptor (TAS2R) pan-agonist. Two...
Browse by tag






bottom of page

